Latest Cancer News

Delaying Lymph Node Biopsy After Melanoma Diagnosis Does Not Affect Survival Rates (07-20-2017)

A lymph node biopsy occurring more than 30 days after diagnosis is unlikely to have an adverse effect on the patient’s overall prognosis Postponing lymph node biopsy more than 30 days after melanoma diagnosis doesn’t adversely impact long-term clinical outcomes according to new study findings published in the Journal of [...]


New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style (07-19-2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA copying errors. The recent discovery challenges the widespread belief that cancer mutations [...]


FDA Approves Nerlynx for Treatment of Early Stage HER2-Positive Breast Cancer (07-18-2017)

The U.S. Food and Drug Administration approved Nerlynx (eratinib) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of Nerlynx following adjuvant trastuzumab treatment. Women (n=2,840) [...]


Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma (07-18-2017)

A clinical trial evaluating Opdivo  (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk of recurrence following complete surgical resection has demonstrated a superior recurrence-free survival in patients receiving Opdivo compared to Yervoy. There remains an unmet need for additional treatment options for individuals with stage III and [...]


Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know (07-17-2017)

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s [...]


Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (07-13-2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated with Revlimid alone were recently presented in an oral session today during the 22nd Congress of the European Hematology [...]


Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (07-12-2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become first CAR-T cell therapy available  Positive ODAC recommendation is latest milestone for CTL019 [...]


Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (07-12-2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells. Lynparza became the [...]


Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising (07-11-2017)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced [...]


First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients (07-6-2017)

Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global [...]


SUNSHINE: Vitamin D Slows Colon Cancer Progression (07-6-2017)

The first-ever completed comparative clinical trial of the use of vitamin D as a colorectal cancer therapy has shown that disease progression is slowed with high-dose supplements according to lead author Kimmie Ng, MD, of the Dana Farber Cancer Institute in Boston, Massachusetts, who presented the study results at the [...]


Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study (07-5-2017)

Data from an ongoing clinical study of tisotumab vedotin in solid tumors has demonstrated activity in the treatment of cervical cancer; 11 of 34 evaluable patients achieved a response; with a median time of treatment of 4.9 months and 7 responders are still ongoing or in follow up for progression. [...]


« Previous PageNext Page »